PURPOSES: To identify biomarkers in epithelial ovarian cancer (EOC) and investigate mechanism of cisplatin-induced activation and expression, 50 genes were screened from 131 ovarian cancer patient samples. Twenty expressed genes were assessed in 30 samples by qPCR. Ovarian cancer cells were treated with cisplatin and studied for expression of cisplatin-activated genes.

RESULTS: Studies of gene signature of histopathological classification TAL2, EGF, ILF3 and UBE21 shown unique expression patterns in EOC histological types. The expression of ILF3 in tumor tissues was significantly higher than normal samples, and especially high in serous carcinomas, compared to mucinous, endometrial and clear cell carcinomas. ILF3 and UBE21 showed overexpression in advanced stage and poorly differentiated patient samples. Investigation of cisplatin-activated signaling indicated increased mRNA expression of ILF3, UBE21 and other kinases involved in cell cycle checkpoint, DNA repair, and apoptosis such as p53, Chk2, c-jun, and hMLH1.

CONCLUSIONS: Overexpression of ILF3 and UBE21 in advanced stage and advanced grade of EOC specimens suggests that these two genes may play important roles in tumorgenesis, tumor progression and pathological differentiation of the disease. Results from in vitro studies demonstrate that activated genes p53, Chk2, c-jun and hMLH1 play a role in chemo-resistance to cisplatin therapy. Further investigation of the molecular mechanisms of the identified genes is warranted.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1697. doi:10.1158/1538-7445.AM2011-1697